CD274 and neoplasm: As indicated in KEYNOTE-240 phase III trial, HCC patients with PDL1 expression in either tumor cells or stroma cells had a similar response to pembrolizumab treatment as compared to those with no PDL1 expression (median survival 16.1 months versus 16.7 months) [44].